FILING ANALYSIS · MONDAY, NOVEMBER 9
ImageneBio, Inc. IMA — 8-K: Results of Operations and Financial Condition
neutral
The company reported a net loss of $15.6 million for the quarter, with R&D expenses decreasing to $11.3 million and G&A expenses decreasing to $6.0 million, and they have $126.6 million in cash to fund operations into the first quarter of 2028. No significant surprises were reported in the filing, with the company's olevaprubart program progressing as planned.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →